文献速递胸部肿瘤

完全切除的II-IIIA期非小细胞肺癌化疗后辅助阿替利珠单抗的总生存:IMpower010随机、多中心、开放标签、III期试验

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
PubMed 文献 · Ann Oncol · 2023-07-17

IMpower010研究在完全切除的IB(≥4 cm)-IIIA期NSCLC患者中,比较铂类化疗后辅助阿替利珠单抗与最佳支持治疗。首次预设总生存期中分析(中位随访45.3个月)显示,ITT人群分层HR为0.995(95%CI 0.78-1.28),中位OS不可估计;PD-L1 TC≥50%的II-IIIA期亚组HR为0.43(95%CI 0.24-0.78)。

要点

  • ITT人群OS分层HR 0.995(95%CI 0.78-1.28),中位OS不可估计。
  • II-IIIA期PD-L1 TC≥50%亚组OS HR 0.43(95%CI 0.24-0.78)。
  • 阿替利珠单抗组3/4级不良事件53例(10.7%),5级4例(0.8%)。

核心结论

  • ITT人群OS数据尚不成熟,PD-L1亚组分析显示有利于阿替利珠单抗的积极趋势,主要由PD-L1 TC≥50%的II-IIIA期亚组驱动。
  • 额外13个月随访后未观察到新的安全性信号,这些发现支持辅助阿替利珠单抗在该 setting 中的正向获益-风险特征。

研究设计与样本

  • III期、开放标签、1:1随机研究,比较阿替利珠单抗(1200 mg 每3周,16周期)与最佳支持治疗,均在辅助铂类化疗(1-4周期)后用于完全切除的IB(≥4 cm)-IIIA期NSCLC成人患者(UICC/AJCC分期系统第7版)。
  • 关键次要终点包括IB-IIIA期意向治疗(ITT)人群的OS和随机化治疗患者的安全性。
  • 首次预设OS期中分析在ITT人群发生251例死亡后进行。
  • 探索性分析包括按基线PD-L1表达水平(SP263检测)评估的OS。

主要发现

  • 截至2022年4月18日,中位随访45.3个月,阿替利珠单抗组507例中127例(25%)死亡,BSC组498例中124例(24.9%)死亡。
  • ITT人群中位OS不可估计,分层HR为0.995(95%CI 0.78-1.28)。
  • II-IIIA期(n=882)分层OS HR为0.95(95%CI 0.74-1.24)。
  • II-IIIA期PD-L1 TC≥1%(n=476)分层OS HR为0.71(95%CI 0.49-1.03)。
  • II-IIIA期PD-L1 TC≥50%(n=229)分层OS HR为0.43(95%CI 0.24-0.78)。

局限性

  • ITT人群OS数据尚不成熟。
  • 原文结论指出这些数据支持辅助阿替利珠单抗在该 setting 中的正向获益-风险特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IMpower010 (NCT02486718) demonstrated significantly improved disease-free survival (DFS) with adjuvant atezolizumab versus best supportive care (BSC) following platinum-based chemotherapy in the programmed death-ligand 1 (PD-L1)-positive and all stage II-IIIA non-small-cell lung cancer (NSCLC) populations, at the DFS interim analysis. Results of the first interim analysis of overall survival (OS) are reported here. PATIENT AND METHODS: The design, participants, and primary-endpoint DFS outcomes have been reported for this phase III, open-label, 1 : 1 randomised study of atezolizumab (1200 mg q3w; 16 cycles) versus BSC after adjuvant platinum-based chemotherapy (1-4 cycles) in adults with completely resected stage IB (≥4 cm)-IIIA NSCLC (per the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system, 7th edition). Key secondary endpoints included OS in the stage IB-IIIA intent-to-treat (ITT) population and safety in randomised treated patients. The first pre-specified interim analysis of OS was conducted after 251 deaths in the ITT population. Exploratory analyses included OS by baseline PD-L1 expression level (SP263 assay). RESULTS: At a median of 45.3 months' follow-up on 18 April 2022, 127 of 507 patients (25%) in the atezolizumab arm and 124 of 498 (24.9%) in the BSC arm had died. The median OS in the ITT population was not estimable; the stratified hazard ratio (HR) was 0.995 [95% confidence interval (CI) 0.78-1.28]. The stratified OS HRs (95% CI) were 0.95 (0.74-1.24) in the stage II-IIIA (n = 882), 0.71 (0.49-1.03) in the stage II-IIIA PD-L1 tumour cell (TC) ≥1% (n = 476), and 0.43 (95% CI 0.24-0.78) in the stage II-IIIA PD-L1 TC ≥50% (n = 229) populations. Atezolizumab-related adverse event incidences remained unchanged since the previous analysis [grade 3/4 in 53 (10.7%) and grade 5 in 4 (0.8%) of 495 patients, respectively]. CONCLUSIONS: Although OS remains immature for the ITT population, these data indicate a positive trend favouring atezolizumab in PD-L1 subgroup analyses, primarily driven by the PD-L1 TC ≥50% stage II-IIIA subgroup. No new safety signals were observed after 13 months' additional follow-up. Together, these findings support the positive benefit-risk profile of adjuvant atezolizumab in this setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023. PMID: 37467930. doi:10.1016/j.annonc.2023.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。